Go back

Imperial researchers to repurpose Covid-19 trial to tackle flu

REMAP-CAP study launched during pandemic will now test multiple flu treatments

Researchers at Imperial College London have repurposed a trial originally set up to tackle Covid-19 to find effective treatments for people hospitalised with severe flu.

First launched during the pandemic, the REMAP-CAP trial works by testing multiple treatments at the same time in thousands of people. The trial name stands for Randomised, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.